Significant association seen for eGFR percentiles below the 25th percentile with risk for kidney failure with replacement ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...

The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), ...

Datopotamab deruxtecan-dlnk received FDA accelerated approval for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy. Clinical trials showed a 45% overall response ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...

Tagrisso significantly improves overall survival in unresectable stage 3 EGFR-mutant NSCLC, surpassing placebo in the LAURA study. The FDA approved Tagrisso in September 2024 for patients with locally ...

Please provide your email address to receive an email when new articles are posted on . The paper provides a race-free equation to estimate kidney filtration in adults with stable kidney function. It ...

Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

When the team knocked out the P2Y2 receptor in drug-resistant cancer cells, it led to an almost complete loss of the mutant EGFR protein.